MyoKardia (MYOK) Tops Q4 EPS by 20c

MyoKardia (NASDAQ: MYOK) reported Q4 EPS of ($0.21), $0.20 better than the analyst estimate of ($0.41). Collaboration & License revenue for the quarter came in at $5.6 million versus the consensus estimate of $6.08 million.

For earnings history and earnings-related data on MyoKardia (MYOK) click here.

You May Also Be Interested In

• Rivian reports record Q3 deliveries, beats estimates, shares rise
• Carnival Corp. (CCL) Tops Q3 EPS by 8c
• Jabil (JBL) Tops Q4 EPS by 34c, Beats on Revenue; Offers FY Guidance